L1CAM and melanoma: In the future, targeting SNCA mRNA with an antisense oligonucleotide (ASO) delivered by tissue specific adenoviral vector together with other chemotherapeutic agents that are currently used for melanoma could be a novel strategy to suppress melanoma metastases by lowering the levels of the key adhesion and signaling molecules, L1CAM and CD81.